MindMed Advances Treatment for Generalized Anxiety Disorder
NEW YORK, NY, December 18, 2023 – Biopharmaceutical company, Mind Medicine (Nasdaq: MNMD) has announced positive results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate) in generalized

